Assessment of immune function and prediction of survival and infection in patients with severe alcoholic hepatitis: An exploratory study

Background and AimAlcoholic hepatitis (AH), a severe complication of long-term alcohol misuse, has a 30% 90-day mortality. Infections are common and associated with higher mortality. There is currently no accurate method to predict infection in these patients. We aimed to test a measure of immune function, the QuantiFERON Monitor (QFM), in predicting clinical outcomes in patients with severe AH. MethodsPeripheral blood was taken at baseline, and QFM performed according to the manufacturer's instructions. In parallel, QFM samples were analyzed with a cytokine multiplex. Clinical outcomes of mortality at 28 and 90 days and development of infection were recorded prospectively. ResultsForty-nine patients were recruited (mean age 51, 59% male and mean discriminant function 57.8). Interferon (IFN)-gamma release measured by standard QFM was significantly higher in survivors compared to non-survivors at 28 (102 vs 16 IU/mL, P = 0.02) and 90 days (115 vs 32 IU/mL; P = 0.046). The area under the receiver operating characteristic curve (AUROC) was 0.79 for 28-day mortality. IFN-gamma, IL-10, and IL-23 release measured by multiplex were significantly lower in patients who developed a subsequent infection compared to those who did not (115 vs 27 IU/mL, P = 0.037; 457 vs 202 pg/mL, P = 0.008; and 1039 vs 663 pg/mL, p = 0.01, respectively). ConclusionImmune dysfunction is associated with poorer outcomes in patients with severe AH. Measurement of IFN-gamma release by standard QFM accurately predicts early mortality, which can be applied to clinical practice as a biomarker of survival. Adaptation of the test to measure IL-10 could be used as a biomarker of subsequent infection to guide clinical treatment decisions.

Automated summary

This study tested the QuantiFERON Monitor (QFM) as a measure of immune function in predicting clinical outcomes in patients with severe alcoholic hepatitis. The findings showed that interferon (IFN)-gamma release measured by standard QFM accurately predicted early mortality at 28 and 90 days in these patients. The measurement of IFN-gamma, IL-10, and IL-23 release also showed potential as a biomarker for subsequent infection.